Company Emerges from Stealth Mode with More Than $20 Million in Seed Financing and Fully Funded Development Alliances with Bayer and Lantheus

BOSTON , June 10, 2022 /PRNewswire/ -- Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin , Ph.D., and John Babich , Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class experts in radiopharmaceuticals discovery and development. The company's near-term plans call for the submission of its first investigational new drug (IND) applications, which are expected this quarter, and the initiation of clinical trials later this year. Based in Boston , Ratio is set to move to a new 19,000-square-foot headquarters and research facility in the Seaport District in January.

Ratio's radiopharmaceuticals strategy is focused on optimizing tumor localization while minimizing uptake by normal tissues. To achieve this, the company uses its proprietary technology platform called Trillium™ that is based on Dr. Babich's prior research at Weill-Cornell Medical College and first developed and validated by the founders in a previous venture. Trillium is a trifunctional small molecule scaffold that can be fine-tuned to alter its plasma clearance, target affinity and therapeutic payload. Each component of the scaffolding can be independently optimized to boost tumor uptake over normal tissue uptake, thereby maximizing therapeutic index. Ratio has successfully applied this framework to several tumor targets and multiple therapeutic payloads.

In addition, Ratio is developing a technology platform to take advantage of the tumor killing power of the alpha emitter, Actinium-225. This proprietary technology is called the Macropa™ chelate platform. Ratio's scientists have already successfully incorporated Macropa into the Trillium platform as well as several peptides and antibodies. Macropa's unique chemistry enables ease of manufacture and robust in vitro and in vivo stability of the resulting radiotherapeutic compound.

"The ability to fine-tune our targeted radiotherapeutics using Trillium and Macropa enables us to address head-on the trifecta of typical challenges we see with most radiopharmaceuticals: delivery, safety and efficacy," said Dr. Babich, Ratio's President and Chief Scientific Officer. "Over the past year, we have generated significant preclinical data that demonstrate our ability to create excellent performing drug candidates that now are advancing into the clinic. Our goal is to become the partner of choice for pharmaceutical companies committed to this area of cancer therapy by enabling the optimization of a broad array of targeting compounds. We will shepherd these therapies through early clinical studies on our own or in collaboration."

Dr. Hoppin, Ratio's Chairman and Chief Executive Officer, added, "Targeted radiotherapy is an exciting and emerging field where chemistry meets physics meets medicine. We have assembled and will continue to build a world-class interdisciplinary team of researchers and developers with a singular focus on delivering these treatments to cancer patients. It isn't often that a start-up company has in place the early financial backing and industry support to advance entirely new drug discoveries to clinical development at this pace. It is with great pride that we announce our formal launch and exit from stealth mode."

In collaboration with Bayer, Ratio has leveraged its Trillium platform for the identification of lead prostate-specific membrane antigen (PSMA)-targeted therapeutic compounds for prostate cancer. At the same time, Ratio is working with Lantheus to develop a lead fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers, such as breast, pancreatic, lung and stomach cancer. Both collaborations are fully funded and reflect the types of partnerships that Ratio is currently pursuing with other companies.

Ratio Therapeutics Inc. is a Boston -based pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. Founded by John Babich , Ph.D., and Jack Hoppin , Ph.D., the company currently employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. Ratio's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety and efficacy properties. The tunable nature of the company's platforms enables the efficient and timely generation of numerous novel radiopharmaceuticals for a broad range of high unmet need in solid tumors. Built to be the radiopharmaceuticals discovery and development partner of choice, Ratio currently collaborates with Bayer and Lantheus.

Please visit www.ratiotx.com for more information and follow us on Twitter and LinkedIn.

Media Contacts: Russo Partners, LLC Erica Fiorini , Ph.D. Erica.fiorini@russopartnersllc.com Kathleen Silverman , Ph.D. Kathleen.silverman@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ratio-therapeutics-launches-to-discover-and-drive-early-clinical-development-of-best-in-class-targeted-radiopharmaceuticals-for-treatment-of-cancers-301565869.html

(Reuters) -The judge overseeing Twitter Inc's $44 billion lawsuit against Elon Musk has a no-nonsense reputation as well as the distinction of being one of the few jurists who has ever ordered a reluctant buyer to close a U.S. corporate merger. Kathaleen McCormick took over the role of chancellor or chief judge of the Court of Chancery last year, the first woman in that role. On Wednesday, she was assigned the Twitter lawsuit which seeks to force Musk to complete his deal for the social media platform, which promises to be one of the biggest legal showdowns in years.

Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) is joining its tech peers in a stock split. The trillion-dollar tech giant, which is the parent company of Google, plans to do a 20:1 stock split on Friday, July 15. If you're aiming to buy Alphabet before the stock split, the clock is ticking.

Rogers knows how to survive — and thrive — in turbulent times.

Intel ( ) is the bearer of additional bad news. The chip giant will give an extra blow to consumers and businesses concerned about the health of the economy. For several weeks in fact, consumers have seen their bills for groceries and other products increase.

The market is unstable. Your portfolio doesn’t need to be.

For nearly six decades, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett has stood head and shoulders above most money managers. Since taking the reins of Berkshire in 1965, Buffett has overseen the creation of more than $610 billion in value for shareholders, as well as led the company's Class A shares (BRK.A) to an aggregate return in excess of 3,600,000%. Given the Oracle of Omaha's incredible track record, investors tend to pay close attention to what he and his investing team are buying and selling.

Mining stocks could capitulate given waning demand for industrial metals

To the oil industry, there is no single price of oil. Instead, there are multiple like Brent, Dubai, and WTI, each for a particular grade of crude. Russia has its own grade of oil—and its price is languishing.

The West Virginia senator retracts his support of clean energy provisions in the Democrats' economic package.

Shares of some of the world's biggest technology companies gained ground on Friday after several difficult sessions for the market. Semiconductor specialist Nvidia (NASDAQ: NVDA) was up as much as 2.4%, social media giant Meta Platforms (NASDAQ: META) rose as much as 3.7%, and customer relationship management (CRM) specialist Salesforce (NYSE: CRM) climbed as much as 3.8%. The catalyst that sent a wide swath of technology stocks higher today was a read on consumer spending, which was more robust than many had predicted.

(Bloomberg) -- Carson Block was on a Delta flight to New York when he felt blood pooling on his seat.Most Read from BloombergIvana Trump, First Wife of Former President, Dies At 73Chinese Homebuyers Across 22 Cities Refuse to Pay MortgagesWall Street Texting Habit Sticks Banks With Rare $1 Billion BillBiden to Leave Mideast With No Immediate Announcement on OilIt’s a tale the famous, filter-free founder of trading firm Muddy Waters Capital launches into to make a point about misdoings among shor

Yahoo Finance's Rachelle Akuffo discusses why Pinterest stock is popping on Thursday.

The head of the company now running the former McDonald's Corp chain of restaurants in Russia told RBC TV that producers of French fries are refusing to supply to the country and warned that attempts to increase domestic processing are fraught with difficulties. McDonald's quit Russia after a Western backlash against Moscow's military campaign in Ukraine, which included a barrage of economic sanctions, and sold all the restaurants it owned to a local licensee in May. CEO Oleg Paroev told Reuters the chain had sold almost 120,000 burgers on opening day.

Russia is positioning itself to engage in 'expropriation blackmail,' according to Mark Dixon, founder of the Moral Rating Agency.

Every investor wants to see his stocks pay off – or he wouldn’t be in the markets. But finding the right investment, the ‘one’ that will bring profits, can sometimes be challenging, especially in today's market conditions. The two simplest courses of action an investor can take to ensure solid returns are based on common sense. The first is to buy low and sell high. That is, find a cheap stock with sound fundamentals and good prospects for growth – and buy in to take advantage of the growth pote

Citigroup Analyst Jim Suva joins Yahoo Finance Live to discuss Apple stock, manufacturing disruptions in China, and product innovation.

Citigroup's latest earnings beat means that it could be priced fairly for once

Most retired workers depend on multiple streams of income during their retirement. Two of the most common such income streams are Social Security and pensions. If we look at pension vs. Social Security income, we find significant differences. Retired workers … Continue reading → The post Pension vs. Social Security: Key Differences appeared first on SmartAsset Blog.

Alphabet stock will undergo a 20-for-1 stock split on July 18. Here's how to trade the stock into the event.

U.S. stocks rallied Friday to cap a four-day losing streak on Wall Street. Sentiment was buoyed by better-than-expected retail sales data and a strong earnings report from Citigroup.